Ondine Biomedical Inc. (LSE:OBI) has seen its Steriwave nasal photodisinfection technology recognised in the UK after a joint project with Mid Yorkshire Teaching NHS Trust won the Excellence in Healthcare Partnership Award. The local evaluation focused on orthopaedic surgery and reported a 71% reduction in surgical site infections in hip procedures, with no infections recorded in knee surgeries over the assessment period, alongside measurable cost savings.
The award win, together with the partnership’s shortlisting for the HSJ Partnership Awards, highlights increasing NHS interest in non-antibiotic approaches to infection prevention as concerns around antimicrobial resistance continue to grow. The results support broader deployment of Steriwave across English hospitals through Ondine’s distribution agreement with Mölnlycke Health Care, reinforcing its role as an alternative to traditional antibiotic-based protocols.
Despite the operational and clinical momentum, the company’s overall outlook remains challenged by financial pressures. Strong revenue growth has yet to translate into profitability or sustained positive cash flow, while technical indicators continue to point to negative share price momentum. Valuation metrics also remain unattractive, reflecting the early-stage and loss-making nature of the business.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specialising in light-activated antimicrobial therapies, known as photodisinfection, for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Its proprietary Steriwave nasal photodisinfection system is approved in several international markets and is under clinical evaluation in the US, with a broader development pipeline targeting areas such as chronic sinusitis, ventilator-associated pneumonia, and burn-related infections.
Leave a Reply